Chad Messer Analyst Performance

Chad Messer serves as a Senior Research Analyst and Managing Director, bringing over 20 years of experience in biotechnology equity research and investor relations. He specializes in providing actionable insights to institutional investors and supporting growth-focused companies in the healthcare and biotech sectors. Before joining Lake Street, Chad served as Vice President of Investor Relations at Cullinan Oncology (NASDAQ: CGEM), leading corporate communications, investor outreach, and strategic messaging. He played a key role in the company’s successful $280 million PIPE financing and expanded analyst coverage. Before that, he held leadership roles at atai Life Sciences (NASDAQ: ATAI). He spent nearly a decade as Managing Director and Senior Biotech Research Analyst at Needham & Company, covering over 25 small- and mid-cap biotech companies. Chad’s career also includes research and business development roles at Piper Jaffray, Paramount BioCapital, and Genaissance Pharmaceuticals, where he negotiated licensing agreements and managed regulatory collaborations. He holds a Ph.D. in Pharmacology from Yale University, where he focused on molecular psychiatry, and an MBA from NYU’s Stern School of Business, specializing in financial instruments and markets.